Long-Stalled FDA Reform Sits On Senateâs Lame-Duck Calendar
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patientsâ safety and doesnât do enough to stop spiraling drug prices.